Brain scans reveal Ocrelizumab's impact on MS inflammation
NCT ID NCT04230174
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how ocrelizumab, a standard MS medication, changes brain inflammation in 22 people with multiple sclerosis. Researchers used special PET and MRI scans to measure inflammation before and after one year of treatment. The goal was to see if the drug reduces harmful immune activity in the brain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Charlestown, Massachusetts, 02129, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?